It explains variations in complement regulatory genes, like CFH and CFI, that play a crucial role in determining clinical outcomes and guiding treatment discontinuation decisions in patients with atypical hemolytic uremic syndrome (aHUS). The authors provide specific criteria for discontinuing complement inhibitor therapy, balancing risks and benefits. Here, CFH is linked to atypical hemolytic-uremic syndrome.